HomeCompareELOX vs JEPQ

ELOX vs JEPQ: Dividend Comparison 2026

ELOX yields 2475.25% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ELOX wins by $73382614261.73M in total portfolio value
10 years
ELOX
ELOX
● Live price
2475.25%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$73382614261.78M
Annual income
$67,980,042,160,694,380.00
Full ELOX calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — ELOX vs JEPQ

📍 ELOX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodELOXJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ELOX + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ELOX pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ELOX
Annual income on $10K today (after 15% tax)
$210,396.04/yr
After 10yr DRIP, annual income (after tax)
$57,783,035,836,590,220.00/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, ELOX beats the other by $57,783,035,836,588,390.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ELOX + JEPQ for your $10,000?

ELOX: 50%JEPQ: 50%
100% JEPQ50/50100% ELOX
Portfolio after 10yr
$36691307130.91M
Annual income
$33,990,021,080,348,268.00/yr
Blended yield
92.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ELOX right now

ELOX
Analyst Ratings
8
Buy
3
Hold
Consensus: Buy
Altman Z
-94.4
Piotroski
2/9
JEPQ
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ELOX buys
0
JEPQ buys
0
No recent congressional trades found for ELOX or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricELOXJEPQ
Forward yield2475.25%11.10%
Annual dividend / share$2.00$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$73382614261.78M$44.8K
Annual income after 10y$67,980,042,160,694,380.00$2,152.59
Total dividends collected$73004868605.64M$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: ELOX vs JEPQ ($10,000, DRIP)

YearELOX PortfolioELOX Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$258,225$247,524.75$11,930$1,110.39+$246.3KELOX
2$6,249,854$5,973,553.08$14,133$1,224.34+$6.24MELOX
3$141,807,743$135,120,399.71$16,632$1,340.46+$141.79MELOX
4$3,017,015,462$2,865,281,177.24$19,454$1,457.97+$3017.00MELOX
5$60,200,153,348$56,971,946,803.11$22,626$1,576.08+$60200.13MELOX
6$1,126,836,870,511$1,062,422,706,429.18$26,175$1,694.09+$1126836.84MELOX
7$19,791,333,921,123$18,585,618,469,676.22$30,133$1,811.32+$19791333.89MELOX
8$326,252,175,090,930$305,075,447,795,328.50$34,531$1,927.17+$326252175.06MELOX
9$5,049,132,804,749,982$4,700,042,977,402,686.00$39,403$2,041.08+$5049132804.71MELOX
10$73,382,614,261,776,860$67,980,042,160,694,380.00$44,787$2,152.59+$73382614261.73MELOX

ELOX vs JEPQ: Complete Analysis 2026

ELOXStock

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

Full ELOX Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this ELOX vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ELOX vs SCHDELOX vs JEPIELOX vs OELOX vs KOELOX vs MAINELOX vs XYLDELOX vs QYLDELOX vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.